DE60125563D1 - Verfahren zur verwendung eines humanen il-17 verwandten polypeptids zur behandlung von krankheiten - Google Patents

Verfahren zur verwendung eines humanen il-17 verwandten polypeptids zur behandlung von krankheiten

Info

Publication number
DE60125563D1
DE60125563D1 DE60125563T DE60125563T DE60125563D1 DE 60125563 D1 DE60125563 D1 DE 60125563D1 DE 60125563 T DE60125563 T DE 60125563T DE 60125563 T DE60125563 T DE 60125563T DE 60125563 D1 DE60125563 D1 DE 60125563D1
Authority
DE
Germany
Prior art keywords
human
treatment
diseases
related polypeptide
immunodeficiencies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Revoked
Application number
DE60125563T
Other languages
English (en)
Other versions
DE60125563T2 (de
Inventor
Lawrence Glasebrook
Ling Liu
Michelle Newton
Jonathan Wendell Tetreault
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26933217&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE60125563(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of DE60125563D1 publication Critical patent/DE60125563D1/de
Application granted granted Critical
Publication of DE60125563T2 publication Critical patent/DE60125563T2/de
Anticipated expiration legal-status Critical
Revoked legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DE60125563T 2000-10-13 2001-09-28 Verfahren zur verwendung eines humanen il-17 verwandten polypeptids zur behandlung von krankheiten Revoked DE60125563T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US24017700P 2000-10-13 2000-10-13
US240177P 2000-10-13
US30993601P 2001-08-03 2001-08-03
US309936P 2001-08-03
PCT/US2001/027737 WO2002033083A2 (en) 2000-10-13 2001-09-28 Methods of using a human il-17-related polypeptide to treat disease

Publications (2)

Publication Number Publication Date
DE60125563D1 true DE60125563D1 (de) 2007-02-08
DE60125563T2 DE60125563T2 (de) 2007-10-04

Family

ID=26933217

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60125563T Revoked DE60125563T2 (de) 2000-10-13 2001-09-28 Verfahren zur verwendung eines humanen il-17 verwandten polypeptids zur behandlung von krankheiten

Country Status (7)

Country Link
US (1) US20060083713A1 (de)
EP (1) EP1326974B1 (de)
AT (1) ATE349523T1 (de)
AU (1) AU2001296229A1 (de)
DE (1) DE60125563T2 (de)
ES (1) ES2277947T3 (de)
WO (1) WO2002033083A2 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7771719B1 (en) 2000-01-11 2010-08-10 Genentech, Inc. Pharmaceutical compositions, kits, and therapeutic uses of antagonist antibodies to IL-17E
EP2333069A3 (de) 1998-05-15 2011-09-14 Genentech, Inc. Therapeutische verwendungen von il-17 homologe polypeptide
EP3112468A1 (de) * 1998-05-15 2017-01-04 Genentech, Inc. Il-17-homologe polypeptide und therapeutische verwendung davon
US7718397B2 (en) 2000-03-21 2010-05-18 Genentech, Inc. Nucleic acids encoding receptor for IL-17 homologous polypeptides and uses thereof
US20030096969A1 (en) 2000-06-02 2003-05-22 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
ES2277947T3 (es) * 2000-10-13 2007-08-01 Eli Lilly And Company Procedimientos de uso de un polipeptido afin a il-17 humana para tratar enfermedades.
CA2491320A1 (en) * 2002-07-15 2004-01-22 Wyeth Methods and compositions for modulating t helper (th) cell development and function
NZ544317A (en) 2003-07-08 2009-05-31 Genentech Inc IL-17 A/F heterologous polypeptides and therapeutic uses thereof
AU2004275871A1 (en) * 2003-09-25 2005-04-07 Zymogenetics, Inc. Methods of treating autoimmune diseases using IL-21
GB0417487D0 (en) 2004-08-05 2004-09-08 Novartis Ag Organic compound
EP1671642A1 (de) 2004-12-15 2006-06-21 Universite D'angers Zusammensetzungen mit (Ant)agonisten von Oncostatin M (OSM), IL-31 und IFN-gamma zur Modulierung der Migration und Funktion von Keratinozyten via einen Rezeptor welcher OSMRbeta als Untereinheit enthält, und entprechende Anwendungen
US10080779B2 (en) 2004-12-15 2018-09-25 Universite D'angers Method for increasing the expression of anti-microbial peptides by keratinocytes comprising administering a composition comprising IL-17, TNF-alpha and OSM
US20090005381A1 (en) * 2007-06-26 2009-01-01 Philip Manton Brown Methods of treating serotonin-mediated diseases and disorders
NZ623706A (en) 2008-05-05 2015-12-24 Novimmune Sa Anti-il-17a/il-17f cross-reactive antibodies and methods of use thereof
US20120076754A1 (en) * 2009-05-20 2012-03-29 Ziad Mallat Use of IL-17 Polypeptides for Use in the Prevention or Treatment of Atherosclerosis
AU2010303166A1 (en) * 2009-10-10 2012-05-24 Eleven Biotherapeutics, Inc. IL-17 family cytokine compositions and uses
US11135268B2 (en) * 2015-07-07 2021-10-05 Fred Hutchinson Cancer Research Center Compositions, kits, and methods using interleukin-17C to promote neural growth and/or neural survival
KR102617833B1 (ko) 2016-05-06 2023-12-27 엑시큐어 오퍼레이팅 컴퍼니 인터류킨 17 수용체 mRNA의 특이적 녹다운을 위한 안티센스 올리고뉴클레오티드 (ASO)를 제시하는 리포좀성 구형 핵산 (SNA) 구축물
CN106153923B (zh) * 2016-06-21 2017-12-05 北京大学第一医院 预测谷丙转氨酶小于二倍正常上限的慢性乙型病毒性肝炎患者肝脏炎症程度的系统
US11696954B2 (en) 2017-04-28 2023-07-11 Exicure Operating Company Synthesis of spherical nucleic acids using lipophilic moieties

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2333069A3 (de) * 1998-05-15 2011-09-14 Genentech, Inc. Therapeutische verwendungen von il-17 homologe polypeptide
WO1999061617A1 (en) * 1998-05-29 1999-12-02 Human Genome Sciences, Inc. Interleukins-21 and 22
AU6277799A (en) * 1998-10-02 2000-04-26 Eli Lilly And Company Il-17 homolog nucleic acids, polypeptides, vectors, host cells, methods and usesthereof
ES2379101T3 (es) * 1999-12-23 2012-04-20 Genentech, Inc. Polipéptidos homólogos IL-17 y usos terapéuticos de los mismos
JP2003523745A (ja) * 2000-02-08 2003-08-12 アムジェン インコーポレイテッド Ｉｌ−１７様分子およびその使用
CA2412626C (en) * 2000-06-22 2013-10-22 Amgen Inc. Il-17 molecules and uses thereof
CN101423551A (zh) * 2000-07-27 2009-05-06 惠氏公司 分离的编码t细胞诱导因子或白介素-21的核酸分子，其编码的蛋白和其应用
ES2277947T3 (es) * 2000-10-13 2007-08-01 Eli Lilly And Company Procedimientos de uso de un polipeptido afin a il-17 humana para tratar enfermedades.

Also Published As

Publication number Publication date
EP1326974B1 (de) 2006-12-27
AU2001296229A1 (en) 2002-04-29
US20060083713A1 (en) 2006-04-20
WO2002033083A2 (en) 2002-04-25
ES2277947T3 (es) 2007-08-01
WO2002033083A3 (en) 2003-03-06
DE60125563T2 (de) 2007-10-04
EP1326974A2 (de) 2003-07-16
ATE349523T1 (de) 2007-01-15

Similar Documents

Publication Publication Date Title
DE60125563D1 (de) Verfahren zur verwendung eines humanen il-17 verwandten polypeptids zur behandlung von krankheiten
DK1368060T3 (da) HMGB1-proteininhibitorer og/eller antagonister til behandlingen af vaskulære sygdomme
NO2016007I2 (no) Susoktokog
ATE355852T1 (de) Verwendung von botulinum toxin zur behandlung von herz- und kreislaufskrankheiten
EA200200755A1 (ru) Опосредованная рецептором nogo блокада роста аксонов
ATE385806T1 (de) Fusionsproteine
WO2000047618A3 (en) HUMAN β-SECRETASE ENZYME, INHIBITORS AND THEIR COMPOSITIONS AND USES
ATE202706T1 (de) Verwendung von 9-deoxyprostaglandinderivaten zur behandlung von glaukom
MX2007013626A (es) Anticuerpos dirigidos contra el peptido beta amiloide y procedimientos que usan los mismos.
DE60032486D1 (de) Prion protein peptide und deren verwendung
MA27880A1 (fr) Derives de tetrahydrocarbazole et leur utilisation pharmaceutique
DE602004025668D1 (de) Methoden der verhinderung und behandlung der alzheimer'schen krankheit
CY1111120T1 (el) Πεπτιδια που παραγονται απο πρωτεϊνες νευρικων ινων και η ιατρικη τους χρηση
ATE459644T1 (de) Verwendung von aspartic proteasen in den bereichen kosmetik und behandlung
DE60319083D1 (de) Pharmazeutische verbindung und methoden zur behandlung von menschlichen karzinomen mittels arginin entzug
DE60140960D1 (de) Verwendung von serp-1 in kombination mit einem immunosuppressor zur behandlung von arthritis
NO20060781L (no) Anvendelse av loselig CD164 ved inflammatoriske og/eller autoimmune lidelser
DE60319135D1 (de) Peptide, die die heparinbindungsdomäne von vegf und vegfr-2 binden
DE69131253T2 (de) Zur behandlung von tumoren und hiv-infektionen nützliches pflanzliches protein
DE602004019541D1 (de) Cycloalkyläbü kondensierte indole
ATE492285T1 (de) Verwendung von kahalalide verbindungen zur herstellung eines arzneimittels zur behandlung von psoriasis
ATE433326T1 (de) Verwendung von löslichem fgl2 als immunosuppressivum
NO20052525D0 (no) Spleisevariant av humant hypofyseveksthormon
DE69420574T2 (de) Derivate von therapeutisch in der blutgerinnungskaskade wirksamen peptiden, verfahren zur herstellung und sie enthaltende pharmazeutische zubereitungen
DE69421705D1 (de) Verwendung von Efaroxan und dessen Derivaten zur Herstellung eines Arzneimittels zur Behandlung neurogenerativer Erkrankungen

Legal Events

Date Code Title Description
8363 Opposition against the patent
8331 Complete revocation